Sydney Spinout Secures $273M Deal to Develop Psychiatric Drugs
Compounds developed by Professor Michael Kassiou’s drug discovery team for Kinoxis Therapeutics will be used to target oxytocin receptors with the aim
Sydney Spinout Secures $273M Deal to Develop Psychiatric Drugs
